$1,843.89 general Payment -- Eli Lilly and Company to Dr. Thomas Miller

Eli Lilly and Company provides $1,843.89 in educational payments to a Washington-based psychiatrist for Eliquis.

This page provides a detailed analysis of a $1,843.89 general payment from Eli Lilly and Company to Dr. Thomas Miller. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$1,843.89
Payment Typegeneral
Payment NatureEducation
Pharmaceutical CompanyEli Lilly and Company
PhysicianDr. Thomas Miller
NPI Number1944633615
Physician SpecialtyPsychiatry
LocationCity, WA
Date of Payment2025-12-14
Related Drug/DeviceEliquis
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Eli Lilly and Company made a $1.8K general payment to Thomas Miller, a Psychiatry specialist in City, WA. The payment was associated with Eliquis. The payment of $1,843.89 to Dr. Thomas Miller from Eli Lilly and Company is categorized as 'Education'. This payment is associated with the drug Eliquis, a common anticoagulant. The payment occurred on December 14, 2025, and was made to a psychiatrist in Washington state.

Patient Guidance: What This Payment Means for You

This payment was for educational purposes related to a medication. It's important to discuss all treatment options and potential side effects with your doctor. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Educational payments to psychiatrists are common in the pharmaceutical industry, but the specific amount and context should be evaluated against industry norms for this specialty.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Sunshine Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $1.8K payment for?

This was a general payment of $1.8K from Eli Lilly and Company to Thomas Miller, categorized as "Education". It was associated with Eliquis. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Thomas Miller accept pharmaceutical money?

Yes, Thomas Miller received this $1.8K payment from Eli Lilly and Company. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Thomas Miller's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $1.8K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Psychiatry?

To compare this payment against Psychiatry averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Psychiatry physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Thomas Miller's relationship with Eli Lilly and Company?

The payment amount is relatively modest. This $1.8K general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Psychiatry?

The payment type is 'general', suggesting it's not tied to specific research or consulting.

What should patients do after learning about this payment?

This payment was for educational purposes related to a medication. It's important to discuss all treatment options and potential side effects with your doctor.

What else should I know about this general payment?

The drug mentioned, Eliquis, is a widely prescribed anticoagulant.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.